Page last updated: 2024-08-16

ribavirin and gs-9256

ribavirin has been researched along with gs-9256 in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Agarwal, K; Arterburn, S; Buggisch, P; Foster, GR; Horsmans, Y; Klinker, H; Knox, S; Manns, MP; Marcellin, P; McHutchison, JG; Mo, H; Moreno, C; Oldach, D; Sereni, D; Zarski, JP; Zeuzem, S	1
Dieterich, DT; Martel-Laferrière, V	1

Reviews

1 review(s) available for ribavirin and gs-9256

Article	Year
Update on combinations of DAAs with and without pegylated-interferon and ribavirin: triple and quadruple therapy more than doubles SVR. Clinics in liver disease, 2013, Volume: 17, Issue:1 Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Peptides, Cyclic; Phosphinic Acids; Polyethylene Glycols; Protease Inhibitors; Quinolines; Ribavirin; Sofosbuvir; Uridine Monophosphate	2013

Article

Year

Update on combinations of DAAs with and without pegylated-interferon and ribavirin: triple and quadruple therapy more than doubles SVR.

Clinics in liver disease, 2013, Volume: 17, Issue:1

Topics: Antiviral Agents; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Interferons; Peptides, Cyclic; Phosphinic Acids; Polyethylene Glycols; Protease Inhibitors; Quinolines; Ribavirin; Sofosbuvir; Uridine Monophosphate

2013

Trials

1 trial(s) available for ribavirin and gs-9256

Article	Year
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:3 Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Peptides, Cyclic; Phosphinic Acids; Polyethylene Glycols; Protease Inhibitors; Purines; Pyridazines; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome	2012

Article

Year

The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.

Hepatology (Baltimore, Md.), 2012, Volume: 55, Issue:3

Topics: Adult; Antiviral Agents; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon-alpha; Male; Middle Aged; Peptides, Cyclic; Phosphinic Acids; Polyethylene Glycols; Protease Inhibitors; Purines; Pyridazines; Recombinant Proteins; Ribavirin; RNA, Viral; Treatment Outcome

2012